Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients With Recurrent Osteosarcoma Localized to the Lung

NCT00752206 is registered in ClinicalTrials.gov with Sarcoma Alliance for Research through Collaboration as lead sponsor.

NCT NCT00752206
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00752206 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Cross-over, Phase II.5 Study of Saracatinib (AZD0530), a Selective Src Kinase Inhibitor, In Patients With Recurrent Osteosarcoma Localized to the Lung
Lead sponsor
Sarcoma Alliance for Research through Collaboration
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2009
Completion date
December 31, 2017
Enrollment
38 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

osteosarcoma